ACA
BHVN

Apis Capital Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Apis Capital Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,000
Closed -$1.2M – 54
2020
Q4 		$1.2M Buy
+14,000
New +$1.19M 1.16% 25
2019
Q3 		$751K Buy
+18,000
New +$760K 1.18% 19

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Apis Capital Advisors's BHVN Position: Q1 2021 in Review

Apis Capital Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 14,000 shares — an estimated $1.2M sold.

Apis Capital Advisors first reported a position in BHVN in Q3 2019 and held it in 2 quarters. The position peaked at $1.2M in Q4 2020. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

  • Apis Capital Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
  • Apis Capital Advisors sold 14,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $1.2M.
  • Apis Capital Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 2 quarters.
  • Apis Capital Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.2M in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Apis Capital Advisors's 13F filing for Q1 2021, filed 14 May 2021.